| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Douglas L Boggs, Deanna L Kelly, Fang Liu, Jared A Linthicum, Hailey Turner, Jennifer R Schroeder, Robert P McMahon, David A Gorelic. Cannabis withdrawal in chronic cannabis users with schizophrenia. Journal of psychiatric research. vol 47. issue 2. 2013-06-07. PMID:23146560. |
cannabis withdrawal in chronic cannabis users with schizophrenia. |
2013-06-07 |
2023-08-12 |
Not clear |
| Douglas L Boggs, Deanna L Kelly, Fang Liu, Jared A Linthicum, Hailey Turner, Jennifer R Schroeder, Robert P McMahon, David A Gorelic. Cannabis withdrawal in chronic cannabis users with schizophrenia. Journal of psychiatric research. vol 47. issue 2. 2013-06-07. PMID:23146560. |
chronic users of cannabis often report withdrawal symptoms after abstinence from use, but little is known about cannabis withdrawal in people with schizophrenia. |
2013-06-07 |
2023-08-12 |
Not clear |
| Victoria S Dalton, Mathieu Verdurand, Adam Walker, Deborah M Hodgson, Katerina Zavitsano. Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. ISRN psychiatry. vol 2012. 2013-06-06. PMID:23738203. |
infections during pregnancy and adolescent cannabis use have both been identified as environmental risk factors for schizophrenia. |
2013-06-06 |
2023-08-12 |
rat |
| Serena Deian. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:23109356. |
cannabidiol: a new light for schizophrenia? |
2013-06-03 |
2023-08-12 |
Not clear |
| Serena Deian. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:23109356. |
evidence suggests an association between cannabis and schizophrenia: schizophrenics show a higher use of marijuana as compared to the healthy population. |
2013-06-03 |
2023-08-12 |
Not clear |
| Anand Gururajan, Elizabeth E Manning, Maren Klug, Maarten van den Buus. Drugs of abuse and increased risk of psychosis development. The Australian and New Zealand journal of psychiatry. vol 46. issue 12. 2013-05-23. PMID:22833579. |
there is considerable evidence to suggest that the abuse of illicit drugs, particularly cannabis and methamphetamine, has aetiological roles in the pathogenesis of psychosis and schizophrenia. |
2013-05-23 |
2023-08-12 |
Not clear |
| Kirsty E Scholes-Balog, Mathew T Martin-Iverso. Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. Human psychopharmacology. vol 26. issue 6. 2013-05-17. PMID:21800361. |
cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. |
2013-05-17 |
2023-08-12 |
Not clear |
| Kirsty E Scholes-Balog, Mathew T Martin-Iverso. Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. Human psychopharmacology. vol 26. issue 6. 2013-05-17. PMID:21800361. |
schizophrenia patients and healthy cannabis users show different attention-dependant alterations in prepulse inhibition (ppi). |
2013-05-17 |
2023-08-12 |
Not clear |
| Kirsty E Scholes-Balog, Mathew T Martin-Iverso. Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. Human psychopharmacology. vol 26. issue 6. 2013-05-17. PMID:21800361. |
it is of interest then to examine ppi in patients with schizophrenia who use cannabis, given the hypothesized association between cannabis use and schizophrenia. |
2013-05-17 |
2023-08-12 |
Not clear |
| K A Gleason, S G Birnbaum, A Shukla, S Ghos. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Translational psychiatry. vol 2. 2013-05-16. PMID:23188199. |
clinical studies report associations between cannabis use during adolescence and later onset of schizophrenia. |
2013-05-16 |
2023-08-12 |
mouse |
| K A Gleason, S G Birnbaum, A Shukla, S Ghos. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Translational psychiatry. vol 2. 2013-05-16. PMID:23188199. |
these data suggest that significant cannabis use during adolescence may be a contributory causal factor in the development of certain features of schizophrenia and may offer mglur5 as a potential therapeutic target. |
2013-05-16 |
2023-08-12 |
mouse |
| Munish Aggarwal, Anindya Banerjee, Shubh Mohan Singh, S K Mattoo, D Bas. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications. Asian journal of psychiatry. vol 5. issue 3. 2013-05-03. PMID:22981049. |
the most common type of psychosis was schizophrenia like psychosis, being more common in the cannabis group. |
2013-05-03 |
2023-08-12 |
human |
| H Bugra, C Rapp, E Studerus, J Aston, S Borgwardt, A Riecher-Rössle. [Can cannabis use increase the risk for schizophrenic psychoses?]. Fortschritte der Neurologie-Psychiatrie. vol 80. issue 11. 2013-04-29. PMID:23139065. |
(ii) patients with schizophrenia abuse cannabis more often than age-matched healthy controls. |
2013-04-29 |
2023-08-12 |
Not clear |
| J C Arnold, A A Boucher, T Kar. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716133. |
the yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| J C Arnold, A A Boucher, T Kar. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716133. |
there is substantial epidemiological evidence showing that cannabis increases the risk of psychosis, whereas other research suggests that schizophrenia patients self-medicate with the substance. |
2013-03-25 |
2023-08-12 |
Not clear |
| Anna Buadze, Stefan Kaiser, Rudolf Stohler, Wulf Roessler, Erich Seifritz, Michael Liebren. Patient's perceptions of the cannabis-psychosis link--a systematic review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716137. |
over the past years a growing research effort has investigated the relation between cannabis use and schizophrenia at a neurobiological, epidemiological and clinical level. |
2013-03-25 |
2023-08-12 |
human |
| Anna Buadze, Stefan Kaiser, Rudolf Stohler, Wulf Roessler, Erich Seifritz, Michael Liebren. Patient's perceptions of the cannabis-psychosis link--a systematic review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716137. |
the vast majority of patients with either schizophrenia or a recent psychosis disagreed with a causal link between cannabis use and their mental illness. |
2013-03-25 |
2023-08-12 |
human |
| Jurgen Gallinat, Johannes Rentzsch, Patrik Rose. Neurophysiological effects of cannabinoids: implications for psychosis research. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716142. |
in particular, cannabis use has the potential to trigger the onset of psychosis in vulnerable individuals and to exacerbate psychotic symptomatology in schizophrenia patients, including positive, negative, and cognitive symptoms. |
2013-03-25 |
2023-08-12 |
human |
| Judit Lazar. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716145. |
psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. |
2013-03-25 |
2023-08-12 |
Not clear |
| Judit Lazar. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716145. |
although cannabis use disorder is strongly related to schizophrenia and treatment of patients with double diagnosis provides serious problem, specific pharmacological, molecular and therapeutical data on this subgroup are poorly available. |
2013-03-25 |
2023-08-12 |
Not clear |